

Curriculum Vitae

Sebastian Kobold

Prof. Dr. med.

d.o.b. August 26th, 1983

University Education

- 2012 – 2017 DPhil, Sir William Dunn School of Pathology, University of Oxford, UK
- 2010 Doctorate in medicine, Grade: magna cum laude (with high honors)
- 2007 State medical boards and successful completion of medical studies, Grade 1,5 (the best grade is 1 on a scale of 1 to 6)
- 2006 - 2007 Electives in Bordeaux, Zürich and Homburg
- 2004 - 2007 Doctoral thesis in the laboratory of Prof. Dr. Renner and Prof. Dr. Knuth in Homburg and Zürich
- 2001 – 2007 Medical studies at the medical faculty of the Saarland University, Homburg, Germany

Scientific Career

- From 2024 Speaker of the Marie-Sklodowska-Curie Innovative Training Network TRAFIC, funded from 2025 – 2029
- 2023 – 2024 Designated Speaker of the Excellence Cluster candidate "Programming Immune cells for Cure" (P12C)
- From 2023 Section Editor, Journal for the Immunotherapy of Cancer (JIF 12.5)
- From 2022 Speaker, Bavarian Cell Therapy Calalysator (BAYCELLator) funded by the Bayerische Forschungsstiftung (from 05/2023)
- From 2022 Associate Editor, ESMO IOTECH
- From 2021 Speaker, Clinician-Scientist Program "Immunoncology and Local Interventions, IOLIN", funded by the Else-Kröner-Fresenius-Stiftung
- From 2020 Elected Board Member, Immunotherapy of Cancer Association (ITOC), Vienna, Austria
Associate Editor, Frontiers in Immunology (JIF 4.8) and Frontiers in Oncology (JIF 5)
- From 2020 Speaker of the Marie-Sklodowska-Curie Innovative Training Network T-OP (Training network for optimizing adoptive cell therapy of cancer), funded from 2021-2025
- 2020 Speaker of the Cluster4future finalist "the Munich cluster for personalized cellular therapies" (PerCELLUM)
- From 2020 Principal investigator in the German Center for Translational Cancer Research (DKTK)
- From 2019 Professor for experimental immunoncology and deputy director, Ludwig-Maximilians-Universität München, Munich, Germany
- From 2018 Head of the laboratory for flow cytometry, medical faculty, inner city campus, Ludwig-Maximilians-Universität München
- From 2018 Associate Editor, Journal for the Immunotherapy of Cancer (JIF 13.6)
- 2018 Visiting Professor, Luigi-Vanitelli-University of Naples, Italy
- From 2016 Attending Physician (Oberarzt), Division of Clinical Pharmacology, Department of Internal Medicine IV, Director: Prof. Dr. Endres
- From 2016 Principal investigator in the German center for lung research, Munich
- 2015 - 2019 Scientific coordinator and applicant of the newly funded Marie-Sklodowska-Curie innovative Training Network "IMMUTRAIN" (Speaker: S. Endres)
- From 2014 Scientific coordinator and applicant of the newly funded international training network "i-Target: immunotargeting of cancer", supported by the Elite Network of Bavaria (Speaker: S. Endres)
- From 2011 Group leader, immunopharmacology group
Division of Clinical Pharmacology, Department of Internal Medicine IV, Director: Prof. Dr. Endres
- From 2011 Head of pharmacogenetic diagnostics

- Division of Clinical Pharmacology, Department of Internal Medicine IV, Director: Prof. Dr. Endres
- 2009 – 2015 Post-Doc and Resident in the Division of Clinical Pharmacology, Department of Internal Medicine IV, Director: Prof. Dr. Endres
- 2008 – 2009 Post-Doc in the laboratory of tumor immunology, University medical center Hamburg-Eppendorf, Head: PD Dr. Atanackovic
- 2008 – 2009 Intern and Resident at the Clinic for oncology, hematology and stem cell transplantation with the section Pneumology, University Medical Center Hamburg-Eppendorf, Director: Prof. Dr. Bokemeyer

Awards and Honors

- 2024 Rolf Becker Award for Medical Research 2024, awarded by the foundation Rufzeichen Gesundheit, Germany
- 2023 Takeda-Research Award in Lung Cancer 2023
- 2023 Georges-Köhler-Award of the German Society for Immunology
- 2022 Cancer Research Award of the Berlin-Brandenburg Academy of Science, sponsored by the Monika-Kutzner Foundation
- 2021 Lisec-Artz-Award for Cancer Research, University of Bonn, Germany
- 2020 Clinical Science Award by the German Society for Immune and targeted Therapies (DGFIT)
- 2019 M4-Award for biomedical entrepreneurship, awarded by the Bavarian Ministry of Economic Affairs
- 2019 Johann-Georg-Zimmermann Preis für Krebsforschung, awarded on February 11th 2019 by Medizinische Hochschule Hannover
- 2017 European Research Council (ERC) Starting Grant
- 2017 Hugo-Wilhelm von Ziemssen Award for medical research, awarded by the University Hospital of the Ludwig-Maximilians-Universität München
- 2016 Vincenz-Czerny Award for cancer research, awarded by the German Society of Hematology and Oncology
- 2016 BMS-MRA Young Investigator Award, awarded by the Melanoma Research Alliance, Washington D.C., US
- 2016 Ernst-Jung Karriereförderpreis 2016, awarded by the Ernst-Jung-Stiftung
- 2015 Habilitation price of the Ludwig-Maximilians Universität München, awarded by "Universitätsgesellschaft"
- 2013 Young Investigator Award of the German, Austrian and Swiss Societies of Hematology and Oncology, awarded on October 21th 2013 in Vienna
- 2013 Stipend of the Bavarian Research Foundation for a three months research visit at the Dana-Farber Cancer Institute; Harvard University in Boston, USA (July through September 2013 in the laboratory of Prof. Kai W. Wucherpfennig)
- 2013 Travel grant from the Glaxosmithkline foundation for the Keystone meeting "Cancer Immunology and Immunotherapy" in Vancouver, Canada
- 2012 Nomination and selection for the Munich-Harvard Young Scientists Forum in Harvard
- 2011 Nomination and selection for the 61. Nobel laureates meeting in Lindau
- 2009 Travel grant to the European Congress of Immunology in Berlin, awarded by the European Federation of Immunological Societies

Five most important Publications

Lacher SB, Dörr J, de Almeida GP, Hönninger J, Bayerl F, Hirschberger A, Pedde AM, Meiser P, Ramsauer L, Rudolph TJ, Spranger N, Morotti M, Grimm AJ, Jarosch S, Oner A, Gregor L, Lesch S, Michaelides S, Fertig L, Briukhovetska D, Majed L, Stock S, Busch DH, Buchholz VR, Knolle PA, Zehn D, Dangaj Laniti D, Kobold S*, Böttcher JP*: PGE2 limits effector expansion of tumour-infiltrating stem-like CD8+ T cells. *Nature*. 2024 May;629(8011):417-425. doi: 10.1038/s41586-024-07254-x. * share senior authorship
JIF: 64,8

Wagenbauer KF, Pham N, Gottschlich A, Kick B, Kozina V, Frank C, Trninic D, Stömmner P, Grünmeier R, Carlini E, Tsiverioti CA, Kobold S*, Funke JJ*, Dietz H*: Programmable multispecific DNA-origami-based T-cell engagers. *Nat Nanotechnol*. 2023 Nov;18(11):1319-1326. doi: 10.1038/s41565-023-01471-7. * share senior authorship
JIF: 40

Gottschlich A, Thomas M, Grünmeier R, Lesch S, Rohrbacher L, Igl V, Briukhovetska D, Benmebarek MR, Vick B, Dede S, Müller K, Xu T, Dhoqina D, Märkl F, Robinson S, Sendelhofert A, Schulz H, Umut Ö, Kavaka V, Tsiverioti CA, Carlini E, Nandi S, Strzalkowski T, Lorenzini T, Stock S, Müller PJ, Dörr J, Seifert M, Cadilha BL, Brabenec R, Röder N, Rataj F, Nüesch M, Modemann F, Wellbrock J, Fiedler W, Kellner C, Beltrán E, Herold T, Paquet D, Jeremias I, von Baumgarten L, Endres S, Subklewe M, Marr C, Kobold S: Single-cell transcriptomic atlas-guided development of CAR-T cells for the treatment of acute myeloid leukemia. *Nat Biotechnol*. 2023 Nov;41(11):1618-1632. doi: 10.1038/s41587-023-01684-0.
JIF: 68

Briukhovetska D, Suarez-Gosalvez J, Voigt C, Markota A, Giannou AD, Schübel M, Jobst J, Zhang T, Dörr J, Märkl F, Majed L, Müller PJ, May P, Gottschlich A, Tokarew N, Lücke J, Oner A, Schwerdtfeger M, Andreu-Sanz D, Grünmeier R, Seifert M, Michaelides S, Hristov M, König LM, Cadilha BL, Mikhaylov O, Anders HJ, Rothenfusser S, Flavell RA, Cerezo-Wallis D, Tejedro C, Soengas MS, Bald T, Huber S, Endres S, Kobold S: T cell-derived interleukin-22 drives the expression of CD155 by cancer cells to suppress NK cell function and promote metastasis. *Immunity*. 2023 Jan 10;56(1):143-161.e11. doi: 10.1016/j.immuni.2022.12.010.
JIF: 43,5

Lesch S, Blumenberg V, Stoiber S, Gottschlich A, Ogonek J, Cadilha BL, Dantes Z, Rataj F, Dorman K, Lutz J, Karches CH, Heise C, Kurzay M, Larimer BM, Grassmann S, Rapp M, Nottebrock A, Kruger S, Tokarew N, Metzger P, Hoerth C, Benmebarek MR, Dhoqina D, Grünmeier R, Seifert M, Oener A, Umut Ö, Joaquina S, Vimeux L, Tran T, Hank T, Baba T, Huynh D, Megens RTA, Janssen KP, Jastroch M, Lamp D, Ruehland S, Di Pilato M, Pruessmann JN, Thomas M, Marr C, Ormanns S, Reischer A, Hristov M, Tartour E, Donnadiou E, Rothenfusser S, Duewell P, König LM, Schnurr M, Subklewe M, Liss AS, Halama N, Reichert M, Mempel TR, Endres S, Kobold S: T cells armed with C-X-C chemokine receptor type 6 enhance adoptive cell therapy for pancreatic tumours. *Nat Biomed Eng*. 2021 Nov;5(11):1246-1260. doi: 10.1038/s41551-021-00737-6.
JIF: 26